Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P10635
UPID:
CP2D6_HUMAN
Alternative names:
CYPIID6; Cholesterol 25-hydroxylase; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase
Alternative UPACC:
P10635; Q16752; Q2XND6; Q2XND7; Q2XNE0; Q6B012; Q6NXU8
Background:
Cytochrome P450 2D6 (CYP2D6), known for its roles as Cholesterol 25-hydroxylase, Cytochrome P450-DB1, and Debrisoquine 4-hydroxylase, is a pivotal enzyme in the metabolism of fatty acids, steroids, and retinoids. It facilitates the insertion of oxygen into substrates and the reduction of another oxygen atom into water, utilizing electrons from NADPH. CYP2D6 is instrumental in the epoxidation of polyunsaturated fatty acids and the metabolism of endocannabinoids and cholesterol, contributing to cellular cholesterol homeostasis and the conversion of all-trans retinol to all-trans retinal.
Therapeutic significance:
Understanding the role of Cytochrome P450 2D6 could open doors to potential therapeutic strategies, especially in modulating the endocannabinoid system and managing cholesterol levels.